DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance 

IMT News Desk
IMT News Desk
· 2 min read
DFE Pharma wins 3rd consecutive EcoVadis Gold Medal for sustainability, top 5% for green electricity, microplastic-free excipients & human rights policy.

DFE Pharma has earned its third consecutive Gold Medal from EcoVadis, the world leader in corporate sustainability assessments, in recognition of its strong performance in the four themes rated: Environment, Labor & Human Rights, Ethics and Sustainable Procurement.

This distinction places DFE Pharma in the top 5% of companies, reflecting the company’s focused efforts to embed environmental, social and governance (ESG) principles across all levels of the organization and throughout all its operations and supply chain. 

Dr. Sven Abend, CEO of DFE Pharma, said, “Our third consecutive Gold Medal reflects the dedication of our teams and partners worldwide and encourages us to keep raising the bar- from supplying the most sustainable lactose and plant-based excipients, to working closely with suppliers on nature-positive sourcing, and building a workplace where people feel safe, valued and able to contribute to success.” 

This third Gold Medal recognizes several recent advances and improvements across DFE Pharma’s sustainability agenda. These include the use of 100% green electricity across all production sites, enabling the company to deliver on its SBTi-approved (Science Based Targets initiative) target ahead of the 2030 schedule, with a 42% reduction in Scope 1 and 2 emissions. The company has also ensured that all its excipients are microplastic-free, as evidenced by biodegradability testing and product-specific data. Another step forward has been the launch of EcoLact 2030™, a pioneering initiative designed to bring greater transparency and verified sustainability to the company’s lactose portfolio. Through EcoLact 2030™, pharmaceutical manufacturers gain access to verified CO₂ data and full value-chain traceability, helping them demonstrate Scope 3 emission reductions without disrupting their operations. 

On the social and governance front, DFE Pharma has strengthened its commitments by establishing its own Human Rights Policy, aligned with the UN Guiding Principles on Business and Human Rights and other leading international standards, with measurable indicators to monitor implementation and progress. Recently, the company has also formally committed to the United Nations Global Compact, integrating its Ten Principles on human rights, labour, environment and anti-corruption into its strategy, culture and day-to-day operations, while ensuring transparency through annual Communication on Progress reporting and active stakeholder engagement. 

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk